Re: Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs

Mike Farrell; Rob Adams; Dirsko J F von Pfeil

doi:10.1016/j.tvjl.2024.106104

Re: Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs

Vet J. 2024 Apr 3:305:106104. doi: 10.1016/j.tvjl.2024.106104. Online ahead of print.

Authors

Mike Farrell¹, Rob Adams², Dirsko J F von Pfeil³

Affiliations

¹ Vetlessons, 82 James Carter Road, Mildenhall, Bury St Edmunds IP28 7DE, UK. Electronic address: mike.farrell.vet@gmail.com.
² Paragon Veterinary Referrals, Paragon Point, Red Hall Crescent, Wakefield WF1 2DF, UK.
³ Small Animal Surgery Locum, PLLC, Dallas, TX, United States.

PMID: 38580157
DOI: 10.1016/j.tvjl.2024.106104

Abstract

We are writing to express our interest in the article entitled "Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs", published in the October, 2021 issue of The Veterinary Journal, Volume 276, 105733, by Krautmann and others.

Keywords: Bedinvetmab; Librela; RPOA; Rapidly progressive osteoarthritis.